伊班膦酸钠治疗肺癌骨转移的临床研究

Clinical study on ibandronate combined with chemotherapy in treatment of lung cancer with bone metastasis

背景与目的:骨骼是肺癌最常见的转移部位。骨转移的并发症如疼痛、功能障碍不仅会降低患者的生活质量,甚至会加快患者的死亡。基于上述情况,本文探讨伊班膦酸钠联合化疗治疗肺癌骨转移的临床作用。方法:2006年6月-2007年6月共收治肺癌骨转移患者64例,随机分为两组:伊班膦酸钠联合化疗组和单纯化疗对照组。对比两组的疼痛缓解率、血清AKP、Ca^(2+)和Scr的变化。结果:研究组骨骼疼痛较对照组有明显缓解(有效率71.1%比42.3%)(P=0.006);研究组治疗后血清AKP和Ca^(2+)较治疗前有明显下降(P<0.05);两组患者血清肌苷在治疗前后无明显改变(P>0.05)。结论:伊班膦酸钠是安全、低毒性药物,其联合化疗有缓解肺癌骨转移疼痛和抑制骨转移的作用。

Background and purpose： The skeleton is the most common site of tumor metastasis in lung cancer. Skeletal complications from bone metastasis, such as severe bone pain, functional impairment, may substantially reduce quality of life, in some situations, may result in death. We explored the efficacy of ibandronate combined with chemotherapy in treatment of lung cancer with bone metastasis. Methods： Sixty-four lung cancer patients with bone metastasis were randomized into two groups： 38 patients in study group received normal chemotherapy combined with ibandronate, and 26 patients in control group received normal chemotherapy only. Results： The response rate of pain relief in the study group and control group was 71.1% and 42.3%, respectively（P=0.006）. In study group, serum alkaline phosphatise and serum calcium was decreased after treatment by ibandronate combined with chemotherapy（P〈0.05）. There were no significant changes in serum Cr after treatment by chemotherapy in the control group and chemotherapy combined with ibandronate in the study group（P〉0.05）. Conclusion： Ibandronate is safe and well tolerated. Ibandronate combined with chemotherapy is effective in relief of the pain caused by bone metastases and may inhibit bone metastasis.